<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02442687</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00062677</org_study_id>
    <nct_id>NCT02442687</nct_id>
  </id_info>
  <brief_title>JKB-121 for the Treatment of Nonalcoholic Steatohepatitis</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo Controlled, Parallel-Group, Phase II Trial of JKB-121 for the Treatment of Nonalcoholic Steatohepatitis (NASH)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Manal Abdelmalek</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety and potential efficacy of two dose levels of JKB-121 (5 mg twice daily
      and 10 mg twice daily) in reducing liver fat and/or liver biochemistry compared to placebo in
      patients with biopsy-proven nonalcoholic steatohepatitis
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      JKB-121 is a long-acting small molecule that is efficacious as a weak antagonist at the TLR-4
      receptor. It is a non-selective opioid antagonist which has been shown to prevent the
      lipopolysaccharide (LPS) induced inflammatory liver injury in a methionine/choline deficient
      diet fed rat model of nonalcoholic fatty liver disease. In vitro, JKB-121 neutralized or
      reduced the LPS-induced release of inflammatory cytokines, deactivated hepatic stellate
      cells, inhibited hepatic stellate cell proliferation, and collagen expression. Inhibition of
      the TLR4 signaling pathway may provide an effective therapy in the prevention of inflammatory
      hepatic injury and hepatic fibrosis in patients with nonalcoholic steatohepatitis. This study
      will evaluate the safety and potential efficacy of two dose levels of JKB-121 (5 mg twice
      daily and 10 mg twice daily) in reducing liver fat and/or liver biochemistry compared to
      placebo in patients with biopsy-proven nonalcoholic steatohepatitis.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 1, 2015</start_date>
  <completion_date type="Actual">September 24, 2017</completion_date>
  <primary_completion_date type="Actual">September 24, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Analysis of MRI-PDFF Change From Baseline to Week 24 (Per Protocol Population)</measure>
    <time_frame>Baseline to week 24</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Analysis of MRI-PDFF Change From Baseline to Week 12 (Per Protocol Population)</measure>
    <time_frame>Baseline to Week 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Analysis of ALT Change From Baseline to Week 24 (Per Protocol Population)</measure>
    <time_frame>Baseline to week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysis of ALT Change From Baseline to Week 12 (Per Protocol Population)</measure>
    <time_frame>Baseline to week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Remission (in Weeks)</measure>
    <time_frame>24 weeks</time_frame>
    <description>Time to remission is the time in weeks from randomization to liver function remission, defined as two consecutive ALT values within normal range (&lt;40 U/L) during the treatment period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in BMI (Body Mass Index)</measure>
    <time_frame>Baseline, week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Hemoglobin A1C</measure>
    <time_frame>Baseline, week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Homeostatic Model Assessment of Insulin Resistance (HOMA-IR)</measure>
    <time_frame>Baseline, week 24</time_frame>
    <description>HOMA-IR was calculated according to the formula: fasting insulin (microU/L) x fasting glucose (nmol/L)/22.5. Optimal Range: 1.0 (0.5-1.4). Lower values represent a better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Cholesterol</measure>
    <time_frame>Baseline, week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Triglycerides</measure>
    <time_frame>Baseline, week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Low Density Lipoprotein (LDL) Cholesterol</measure>
    <time_frame>Baseline, week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in High Density Lipoprotein (HDL)</measure>
    <time_frame>Baseline, week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Serum Aspartate Aminotransferase (AST)</measure>
    <time_frame>weeks 4, 8, 12, 16, 20, and 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Serum Alanine Aminotransferase (ALT)</measure>
    <time_frame>weeks 4, 8, 12, 16, 20, and 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Serum Gamma-glutamyl Transpeptidase (GGT)</measure>
    <time_frame>weeks 4, 8, 12, 16, 20, and 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With ALT in Normal Range at Week 24</measure>
    <time_frame>Week 24</time_frame>
    <description>Normal range is &lt;40 U/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Concentrations (Cmax)</measure>
    <time_frame>pre-dose and at 0.25, 0.5, 0.75, 1.0, 1.5, 2.0, 3.0, 4.0, 6.0, 8.0, 10, 12, and 24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum Observed Concentration (Cmin)</measure>
    <time_frame>pre-dose and at 0.25, 0.5, 0.75, 1.0, 1.5, 2.0, 3.0, 4.0, 6.0, 8.0, 10, 12, and 24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under Concentration-time (AUC)</measure>
    <time_frame>pre-dose and at 0.25, 0.5, 0.75, 1.0, 1.5, 2.0, 3.0, 4.0, 6.0, 8.0, 10, 12, and 24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half-life</measure>
    <time_frame>pre-dose and at 0.25, 0.5, 0.75, 1.0, 1.5, 2.0, 3.0, 4.0, 6.0, 8.0, 10, 12, and 24 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">65</enrollment>
  <condition>Nonalcoholic Steatohepatitis</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>JKB 121, 5 mg twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>JKB 121, 10 mg twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Identical appearing placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JKB-121: 5 mg twice daily</intervention_name>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JKB-121: 10 mg twice daily</intervention_name>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age ≥ 18 years

          2. Provision of written informed consent

          3. Biopsy-proven NASH within 12 months or at screening

          4. ALT &gt; 40 U/L for women and &gt; 60 U/L for men at screening and at least once in the
             previous 12 months.

          5. HBA1C of ≤ 9.0

        Exclusion Criteria:

          1. Any chronic liver disease other than NASH

          2. Cirrhosis, as assessed clinically or histologically

          3. Presence of vascular liver disease

          4. BMI ≤ 25 kg/m2

          5. Excessive alcohol use (&gt; 20 g/day) within the past 2 years

          6. AST or ALT &gt; 250 U/L.

          7. Type 1 diabetes mellitus

          8. Bariatric surgery in the past 5 years.

          9. Weight gain of &gt; 5% in past 6 months or &gt; 10% change in past 12 months.

         10. Contraindication to MRI

         11. Inadequate venous access

         12. HIV antibody positive, hepatitis B surface antigen positive (HBsAg), or Hepatitis C
             virus (HCV) RNA positive.

         13. Receiving an elemental diet or parenteral nutrition

         14. Chronic pancreatitis or pancreatic insufficiency

         15. Any history of complications of cirrhosis

         16. Concurrent conditions:

               -  Inflammatory bowel disease

               -  Significant cardiac disease

               -  chronic infection or immune mediated disease

               -  Any malignant disease

               -  Prior solid organ transplant

               -  Any other concurrent condition which, in the opinion of the investigator, could
                  impact adversely on the subject participating or the interpretation of the study
                  data.

         17. Concurrent medications which may treat NASH

         18. HbA1C &gt; 9.0%

         19. Pregnancy or breastfeeding.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Manal F Abdelmalek, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Digestive Disease Specialists of the Southeast</name>
      <address>
        <city>Dothan</city>
        <state>Alabama</state>
        <zip>36305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University Feinberg School of Medicine</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Digestive Associates</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Digestive Disease Specialists</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brook Army Medical Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>78234</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Virginia Health Systems</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical College of Virginia</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>April 7, 2015</study_first_submitted>
  <study_first_submitted_qc>May 12, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 13, 2015</study_first_posted>
  <results_first_submitted>August 24, 2018</results_first_submitted>
  <results_first_submitted_qc>December 7, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">January 7, 2019</results_first_posted>
  <last_update_submitted>December 7, 2018</last_update_submitted>
  <last_update_submitted_qc>December 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 7, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Duke University</investigator_affiliation>
    <investigator_full_name>Manal Abdelmalek</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 2, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/87/NCT02442687/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 31, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/87/NCT02442687/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>JKB 5 mg BID</title>
          <description>JKB 121, 5 mg by mouth twice daily</description>
        </group>
        <group group_id="P2">
          <title>JKB 10 mg BID</title>
          <description>JKB 121, 10 mg by mouth twice daily</description>
        </group>
        <group group_id="P3">
          <title>Placebo BID</title>
          <description>Identical appearing placebo by mouth twice daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="22"/>
                <participants group_id="P3" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>JKB 5 mg BID</title>
          <description>JKB 121, 5 mg twice daily</description>
        </group>
        <group group_id="B2">
          <title>JKB 10 mg BID</title>
          <description>JKB 121, 10 mg twice daily</description>
        </group>
        <group group_id="B3">
          <title>Placebo BID</title>
          <description>Identical appearing placebo</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="21"/>
            <count group_id="B2" value="22"/>
            <count group_id="B3" value="22"/>
            <count group_id="B4" value="65"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="56"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51" spread="11.5"/>
                    <measurement group_id="B2" value="50.5" spread="12.9"/>
                    <measurement group_id="B3" value="49.5" spread="10.5"/>
                    <measurement group_id="B4" value="51" spread="11.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="44"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="50"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="62"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <units>kg/m^2</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40.0" spread="6.8"/>
                    <measurement group_id="B2" value="34.1" spread="6.4"/>
                    <measurement group_id="B3" value="35.4" spread="6.5"/>
                    <measurement group_id="B4" value="35.2" spread="6.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Analysis of MRI-PDFF Change From Baseline to Week 24 (Per Protocol Population)</title>
        <time_frame>Baseline to week 24</time_frame>
        <population>The per protocol population included only those patients with non-missing baseline (ie. screening) and the specified visit are included. If missing, the last valid measurement on or prior to the first date administration of study medication is used as baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>JKB 121, 5 mg</title>
            <description>JKB 121, 5 mg twice daily
JKB-121: 5 mg twice daily</description>
          </group>
          <group group_id="O2">
            <title>JKB-121: 10 mg</title>
            <description>JKB 121, 10 mg twice daily
JKB-121: 10 mg twice daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Identical appearing placebo
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Analysis of MRI-PDFF Change From Baseline to Week 24 (Per Protocol Population)</title>
          <population>The per protocol population included only those patients with non-missing baseline (ie. screening) and the specified visit are included. If missing, the last valid measurement on or prior to the first date administration of study medication is used as baseline.</population>
          <units>percentage of fat</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.38" lower_limit="-1.95" upper_limit="2.72"/>
                    <measurement group_id="O2" value="-0.44" lower_limit="-3.63" upper_limit="2.74"/>
                    <measurement group_id="O3" value="-3.09" lower_limit="-5.28" upper_limit="-0.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.034</p_value>
            <p_value_desc>The p-value was not adjusted for multiple comparison. The threshold for statistical significance was &lt;0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Change from baseline as the dependent variable, baseline value as a covariate, and treatment group and diabetes stratum as factors.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.1731</p_value>
            <p_value_desc>The p-value was not adjusted for multiple comparison. The threshold for statistical significance was &lt;0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Change from baseline as the dependent variable, baseline value as a covariate, and treatment group and diabetes stratum as factors.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Analysis of MRI-PDFF Change From Baseline to Week 12 (Per Protocol Population)</title>
        <time_frame>Baseline to Week 12</time_frame>
        <population>The per protocol population included only those patients with non-missing baseline (ie. screening) and the specified visit are included. If missing, the last valid measurement on or prior to the first date administration of study medication is used as baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>JKB 121, 5 mg</title>
            <description>JKB 121, 5 mg twice daily
JKB-121: 5 mg twice daily</description>
          </group>
          <group group_id="O2">
            <title>JKB 121, 10 mg</title>
            <description>JKB 121, 10 mg twice daily
JKB-121: 10 mg twice daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Identical appearing placebo
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Analysis of MRI-PDFF Change From Baseline to Week 12 (Per Protocol Population)</title>
          <population>The per protocol population included only those patients with non-missing baseline (ie. screening) and the specified visit are included. If missing, the last valid measurement on or prior to the first date administration of study medication is used as baseline.</population>
          <units>percentage</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.78" lower_limit="-4.05" upper_limit="0.50"/>
                    <measurement group_id="O2" value="-1.50" lower_limit="-4.56" upper_limit="1.56"/>
                    <measurement group_id="O3" value="-2.74" lower_limit="-4.78" upper_limit="-0.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.5276</p_value>
            <p_value_desc>The p-value is not adjusted for multiple comparisons. The threshold for statistical significance was &lt;0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The change from baseline as the dependent variable, baseline value as a covariate, and treatment group and diabetes stratum as factors.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.4968</p_value>
            <p_value_desc>The p-value is not adjusted for multiple comparisons. The threshold for statistical significance was &lt;0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The change from baseline as the dependent variable, baseline value as a covariate, and treatment group and diabetes stratum as factors.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Analysis of ALT Change From Baseline to Week 24 (Per Protocol Population)</title>
        <time_frame>Baseline to week 24</time_frame>
        <population>The per protocol population included only those patients with non-missing baseline (ie. screening) and the specified visit are included. If missing, the last valid measurement on or prior to the first date administration of study medication is used as baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>JKB 121, 5 mg</title>
            <description>JKB 121, 5 mg twice daily
JKB-121: 5 mg twice daily</description>
          </group>
          <group group_id="O2">
            <title>JKB 121, 10 mg</title>
            <description>JKB 121, 10 mg twice daily
JKB-121: 10 mg twice daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Identical appearing placebo
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Analysis of ALT Change From Baseline to Week 24 (Per Protocol Population)</title>
          <population>The per protocol population included only those patients with non-missing baseline (ie. screening) and the specified visit are included. If missing, the last valid measurement on or prior to the first date administration of study medication is used as baseline.</population>
          <units>U/L</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.7" lower_limit="-25.2" upper_limit="11.8"/>
                    <measurement group_id="O2" value="-1.3" lower_limit="-25.6" upper_limit="23.0"/>
                    <measurement group_id="O3" value="-20.9" lower_limit="-37.7" upper_limit="-4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.2591</p_value>
            <p_value_desc>The p-value is not adjusted for multiple comparisons. The threshold for statistical significance was &lt;0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Change from baseline as the dependent variable, baseline value as a covariate, and treatment group and diabetes stratum as factors.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.1806</p_value>
            <p_value_desc>The p-value is not adjusted for multiple comparisons. The threshold for statistical significance was &lt;0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Change from baseline as the dependent variable, baseline value as a covariate, and treatment group and diabetes stratum as factors.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Analysis of ALT Change From Baseline to Week 12 (Per Protocol Population)</title>
        <time_frame>Baseline to week 12</time_frame>
        <population>The per protocol population included only those patients with non-missing baseline (ie. screening) and the specified visit are included. If missing, the last valid measurement on or prior to the first date administration of study medication is used as baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>JKB 121, 5 mg</title>
            <description>JKB 121, 5 mg twice daily
JKB-121: 5 mg twice daily</description>
          </group>
          <group group_id="O2">
            <title>JKB 121, 10 mg</title>
            <description>JKB 121, 10 mg twice daily
JKB-121: 10 mg twice daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Identical appearing placebo
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Analysis of ALT Change From Baseline to Week 12 (Per Protocol Population)</title>
          <population>The per protocol population included only those patients with non-missing baseline (ie. screening) and the specified visit are included. If missing, the last valid measurement on or prior to the first date administration of study medication is used as baseline.</population>
          <units>U/L</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.3" lower_limit="-19.5" upper_limit="6.9"/>
                    <measurement group_id="O2" value="-9.9" lower_limit="-27.2" upper_limit="7.4"/>
                    <measurement group_id="O3" value="-21.7" lower_limit="-33.7" upper_limit="-9.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0882</p_value>
            <p_value_desc>The p-value is not adjusted for multiple comparisons. The threshold for statistical significance was &lt;0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The change from baseline as the dependent variable, baseline value as a covariate, and treatment group and diabetes stratum as factors.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.2530</p_value>
            <p_value_desc>The p-value is not adjusted for multiple comparisons. The threshold for statistical significance was &lt;0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The change from baseline as the dependent variable, baseline value as a covariate, and treatment group and diabetes stratum as factors.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Remission (in Weeks)</title>
        <description>Time to remission is the time in weeks from randomization to liver function remission, defined as two consecutive ALT values within normal range (&lt;40 U/L) during the treatment period.</description>
        <time_frame>24 weeks</time_frame>
        <population>No subjects reached remission; analysis not performed.</population>
        <group_list>
          <group group_id="O1">
            <title>JKB 121, 5 mg</title>
            <description>JKB 121, 5 mg twice daily
JKB-121: 5 mg twice daily</description>
          </group>
          <group group_id="O2">
            <title>JKB 121, 10 mg</title>
            <description>JKB 121, 10 mg twice daily
JKB-121: 10 mg twice daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Identical appearing placebo
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Remission (in Weeks)</title>
          <description>Time to remission is the time in weeks from randomization to liver function remission, defined as two consecutive ALT values within normal range (&lt;40 U/L) during the treatment period.</description>
          <population>No subjects reached remission; analysis not performed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in BMI (Body Mass Index)</title>
        <time_frame>Baseline, week 24</time_frame>
        <population>Only patients with non-missing baseline and the specified visit are included.</population>
        <group_list>
          <group group_id="O1">
            <title>JKB 121, 5 mg</title>
            <description>JKB 121, 5 mg twice daily
JKB-121: 5 mg twice daily</description>
          </group>
          <group group_id="O2">
            <title>JKB 121, 10 mg</title>
            <description>JKB 121, 10 mg twice daily
JKB-121: 10 mg twice daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Identical appearing placebo
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in BMI (Body Mass Index)</title>
          <population>Only patients with non-missing baseline and the specified visit are included.</population>
          <units>kg/m^2</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.18" lower_limit="-0.81" upper_limit="0.44"/>
                    <measurement group_id="O2" value="0.54" lower_limit="-0.21" upper_limit="1.30"/>
                    <measurement group_id="O3" value="-0.63" lower_limit="-1.20" upper_limit="-0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Hemoglobin A1C</title>
        <time_frame>Baseline, week 24</time_frame>
        <population>Only patients with non-missing baseline and the specified visit are included</population>
        <group_list>
          <group group_id="O1">
            <title>JKB 121, 5 mg</title>
            <description>JKB 121, 5 mg twice daily
JKB-121: 5 mg twice daily</description>
          </group>
          <group group_id="O2">
            <title>JKB 121, 10 mg</title>
            <description>JKB 121, 10 mg twice daily
JKB-121: 10 mg twice daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Identical appearing placebo
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Hemoglobin A1C</title>
          <population>Only patients with non-missing baseline and the specified visit are included</population>
          <units>percentage of HbA1C</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.07" lower_limit="-0.49" upper_limit="0.63"/>
                    <measurement group_id="O2" value="0.23" lower_limit="-0.44" upper_limit="0.91"/>
                    <measurement group_id="O3" value="0.45" lower_limit="-0.08" upper_limit="0.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Homeostatic Model Assessment of Insulin Resistance (HOMA-IR)</title>
        <description>HOMA-IR was calculated according to the formula: fasting insulin (microU/L) x fasting glucose (nmol/L)/22.5. Optimal Range: 1.0 (0.5-1.4). Lower values represent a better outcome.</description>
        <time_frame>Baseline, week 24</time_frame>
        <population>Only patients with non-missing baseline and the specified visit are included.</population>
        <group_list>
          <group group_id="O1">
            <title>JKB 121, 5 mg</title>
            <description>JKB 121, 5 mg twice daily
JKB-121: 5 mg twice daily</description>
          </group>
          <group group_id="O2">
            <title>JKB 121, 10 mg</title>
            <description>JKB 121, 10 mg twice daily
JKB-121: 10 mg twice daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Identical appearing placebo
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Homeostatic Model Assessment of Insulin Resistance (HOMA-IR)</title>
          <description>HOMA-IR was calculated according to the formula: fasting insulin (microU/L) x fasting glucose (nmol/L)/22.5. Optimal Range: 1.0 (0.5-1.4). Lower values represent a better outcome.</description>
          <population>Only patients with non-missing baseline and the specified visit are included.</population>
          <units>HOMA-IR index</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.013" lower_limit="-3.831" upper_limit="1.805"/>
                    <measurement group_id="O2" value="-0.679" lower_limit="-4.132" upper_limit="2.775"/>
                    <measurement group_id="O3" value="-0.404" lower_limit="-3.039" upper_limit="2.231"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Cholesterol</title>
        <time_frame>Baseline, week 24</time_frame>
        <group_list>
          <group group_id="O1">
            <title>JKB 121, 5 mg</title>
            <description>JKB 121, 5 mg twice daily
JKB-121: 5 mg twice daily</description>
          </group>
          <group group_id="O2">
            <title>JKB 121, 10 mg</title>
            <description>JKB 121, 10 mg twice daily
JKB-121: 10 mg twice daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Identical appearing placebo
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Cholesterol</title>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.62" lower_limit="-0.42" upper_limit="13.66"/>
                    <measurement group_id="O2" value="-2.55" lower_limit="-11.03" upper_limit="5.94"/>
                    <measurement group_id="O3" value="2.26" lower_limit="-4.18" upper_limit="8.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Triglycerides</title>
        <time_frame>Baseline, week 24</time_frame>
        <population>Only patients with non-missing baseline and the specified visit are included.</population>
        <group_list>
          <group group_id="O1">
            <title>JKB 121, 5 mg</title>
            <description>JKB 121, 5 mg twice daily
JKB-121: 5 mg twice daily</description>
          </group>
          <group group_id="O2">
            <title>JKB 121, 10 mg</title>
            <description>JKB 121, 10 mg twice daily
JKB-121: 10 mg twice daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Identical appearing placebo
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Triglycerides</title>
          <population>Only patients with non-missing baseline and the specified visit are included.</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.12" lower_limit="0.94" upper_limit="35.30"/>
                    <measurement group_id="O2" value="2.62" lower_limit="-18.14" upper_limit="23.38"/>
                    <measurement group_id="O3" value="3.78" lower_limit="-11.96" upper_limit="19.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Low Density Lipoprotein (LDL) Cholesterol</title>
        <time_frame>Baseline, week 24</time_frame>
        <population>Only patients with non-missing baseline and the specified visit are included.</population>
        <group_list>
          <group group_id="O1">
            <title>JKB 121, 5 mg</title>
            <description>JKB 121, 5 mg twice daily
JKB-121: 5 mg twice daily</description>
          </group>
          <group group_id="O2">
            <title>JKB 121, 10 mg</title>
            <description>JKB 121, 10 mg twice daily
JKB-121: 10 mg twice daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Identical appearing placebo
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Low Density Lipoprotein (LDL) Cholesterol</title>
          <population>Only patients with non-missing baseline and the specified visit are included.</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.92" lower_limit="-5.57" upper_limit="17.41"/>
                    <measurement group_id="O2" value="-4.79" lower_limit="-18.73" upper_limit="9.15"/>
                    <measurement group_id="O3" value="1.50" lower_limit="-9.58" upper_limit="12.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in High Density Lipoprotein (HDL)</title>
        <time_frame>Baseline, week 24</time_frame>
        <population>Only patients with non-missing baseline and the specified visit are included.</population>
        <group_list>
          <group group_id="O1">
            <title>JKB 121, 5 mg</title>
            <description>JKB 121, 5 mg twice daily
JKB-121: 5 mg twice daily</description>
          </group>
          <group group_id="O2">
            <title>JKB 121, 10 mg</title>
            <description>JKB 121, 10 mg twice daily
JKB-121: 10 mg twice daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Identical appearing placebo
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in High Density Lipoprotein (HDL)</title>
          <population>Only patients with non-missing baseline and the specified visit are included.</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.70" lower_limit="-7.01" upper_limit="12.41"/>
                    <measurement group_id="O2" value="-0.80" lower_limit="-12.54" upper_limit="10.94"/>
                    <measurement group_id="O3" value="13.97" lower_limit="5.09" upper_limit="22.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Serum Aspartate Aminotransferase (AST)</title>
        <time_frame>weeks 4, 8, 12, 16, 20, and 24</time_frame>
        <population>Number of subjects with a result at baseline and the specified visit. Baseline is defined as the measurement at Day 1.</population>
        <group_list>
          <group group_id="O1">
            <title>JKB 121, 5 mg</title>
            <description>JKB 121, 5 mg twice daily
JKB-121: 5 mg twice daily</description>
          </group>
          <group group_id="O2">
            <title>JKB 121, 10 mg</title>
            <description>JKB 121, 10 mg twice daily
JKB-121: 10 mg twice daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Identical appearing placebo
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Serum Aspartate Aminotransferase (AST)</title>
          <population>Number of subjects with a result at baseline and the specified visit. Baseline is defined as the measurement at Day 1.</population>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.7" spread="15.11"/>
                    <measurement group_id="O2" value="42.9" spread="12.01"/>
                    <measurement group_id="O3" value="81.0" spread="79.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.3" spread="16.43"/>
                    <measurement group_id="O2" value="47.1" spread="15.12"/>
                    <measurement group_id="O3" value="67.4" spread="55.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.6" spread="17.56"/>
                    <measurement group_id="O2" value="44.2" spread="16.48"/>
                    <measurement group_id="O3" value="49.7" spread="22.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.9" spread="13.61"/>
                    <measurement group_id="O2" value="47.5" spread="22.29"/>
                    <measurement group_id="O3" value="51.1" spread="24.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.1" spread="26.34"/>
                    <measurement group_id="O2" value="46.4" spread="27.14"/>
                    <measurement group_id="O3" value="54.0" spread="44.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.4" spread="17.92"/>
                    <measurement group_id="O2" value="49.5" spread="33.78"/>
                    <measurement group_id="O3" value="47.4" spread="25.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Serum Alanine Aminotransferase (ALT)</title>
        <time_frame>weeks 4, 8, 12, 16, 20, and 24</time_frame>
        <population>Number of subjects with a result at baseline and the specified visit. Baseline is defined as the measurement at Day 1.</population>
        <group_list>
          <group group_id="O1">
            <title>JKB 121, 5 mg</title>
            <description>JKB 121, 5 mg twice daily
JKB-121: 5 mg twice daily</description>
          </group>
          <group group_id="O2">
            <title>JKB 121, 10 mg</title>
            <description>JKB 121, 10 mg twice daily
JKB-121: 10 mg twice daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Identical appearing placebo
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Serum Alanine Aminotransferase (ALT)</title>
          <population>Number of subjects with a result at baseline and the specified visit. Baseline is defined as the measurement at Day 1.</population>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.8" spread="28.28"/>
                    <measurement group_id="O2" value="70.4" spread="26.33"/>
                    <measurement group_id="O3" value="95.0" spread="66.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.8" spread="26.03"/>
                    <measurement group_id="O2" value="77.4" spread="41.18"/>
                    <measurement group_id="O3" value="79.4" spread="42.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.9" spread="36.23"/>
                    <measurement group_id="O2" value="65.3" spread="28.09"/>
                    <measurement group_id="O3" value="69.8" spread="39.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.5" spread="29.06"/>
                    <measurement group_id="O2" value="69.5" spread="43.98"/>
                    <measurement group_id="O3" value="68.7" spread="33.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.1" spread="33.08"/>
                    <measurement group_id="O2" value="63.8" spread="37.96"/>
                    <measurement group_id="O3" value="70.7" spread="43.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.3" spread="33.80"/>
                    <measurement group_id="O2" value="68.2" spread="46.34"/>
                    <measurement group_id="O3" value="67.6" spread="48.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Serum Gamma-glutamyl Transpeptidase (GGT)</title>
        <time_frame>weeks 4, 8, 12, 16, 20, and 24</time_frame>
        <population>Number of subjects with a result at baseline and the specified visit. Baseline is defined as the measurement at Day 1.</population>
        <group_list>
          <group group_id="O1">
            <title>JKB 121, 5 mg</title>
            <description>JKB 121, 5 mg twice daily
JKB-121: 5 mg twice daily</description>
          </group>
          <group group_id="O2">
            <title>JKB 121, 10 mg</title>
            <description>JKB 121, 10 mg twice daily
JKB-121: 10 mg twice daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Identical appearing placebo
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Serum Gamma-glutamyl Transpeptidase (GGT)</title>
          <population>Number of subjects with a result at baseline and the specified visit. Baseline is defined as the measurement at Day 1.</population>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.4" spread="38.07"/>
                    <measurement group_id="O2" value="83.8" spread="48.85"/>
                    <measurement group_id="O3" value="165.0" spread="149.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.7" spread="48.74"/>
                    <measurement group_id="O2" value="74.6" spread="35.02"/>
                    <measurement group_id="O3" value="147.5" spread="123.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.2" spread="58.32"/>
                    <measurement group_id="O2" value="74.3" spread="36.99"/>
                    <measurement group_id="O3" value="133.8" spread="115.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.3" spread="54.85"/>
                    <measurement group_id="O2" value="69.8" spread="33.49"/>
                    <measurement group_id="O3" value="134.7" spread="139.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.4" spread="52.80"/>
                    <measurement group_id="O2" value="64.1" spread="30.65"/>
                    <measurement group_id="O3" value="132.9" spread="144.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.6" spread="79.47"/>
                    <measurement group_id="O2" value="68.2" spread="30.79"/>
                    <measurement group_id="O3" value="109.7" spread="92.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With ALT in Normal Range at Week 24</title>
        <description>Normal range is &lt;40 U/L</description>
        <time_frame>Week 24</time_frame>
        <population>Number of subjects with an ALT result at the specified visit</population>
        <group_list>
          <group group_id="O1">
            <title>JKB 121, 5 mg</title>
            <description>JKB 121, 5 mg twice daily
JKB-121: 5 mg twice daily</description>
          </group>
          <group group_id="O2">
            <title>JKB 121, 10 mg</title>
            <description>JKB 121, 10 mg twice daily
JKB-121: 10 mg twice daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Identical appearing placebo
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With ALT in Normal Range at Week 24</title>
          <description>Normal range is &lt;40 U/L</description>
          <population>Number of subjects with an ALT result at the specified visit</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Observed Concentrations (Cmax)</title>
        <time_frame>pre-dose and at 0.25, 0.5, 0.75, 1.0, 1.5, 2.0, 3.0, 4.0, 6.0, 8.0, 10, 12, and 24 hours</time_frame>
        <population>PK Substudy Population</population>
        <group_list>
          <group group_id="O1">
            <title>JKB 121, 5 mg</title>
            <description>JKB 121, 5 mg twice daily
JKB-121: 5 mg twice daily</description>
          </group>
          <group group_id="O2">
            <title>JKB 121, 10 mg</title>
            <description>JKB 121, 10 mg twice daily
JKB-121: 10 mg twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Observed Concentrations (Cmax)</title>
          <population>PK Substudy Population</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.26" spread="1.731"/>
                    <measurement group_id="O2" value="14.33" spread="1.986"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Minimum Observed Concentration (Cmin)</title>
        <time_frame>pre-dose and at 0.25, 0.5, 0.75, 1.0, 1.5, 2.0, 3.0, 4.0, 6.0, 8.0, 10, 12, and 24 hours</time_frame>
        <population>PK Substudy Population</population>
        <group_list>
          <group group_id="O1">
            <title>JKB 121, 5 mg</title>
            <description>JKB 121, 5 mg twice daily
JKB-121: 5 mg twice daily</description>
          </group>
          <group group_id="O2">
            <title>JKB 121, 10 mg</title>
            <description>JKB 121, 10 mg twice daily
JKB-121: 10 mg twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Minimum Observed Concentration (Cmin)</title>
          <population>PK Substudy Population</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.349" spread="0.1595"/>
                    <measurement group_id="O2" value="1.512" spread="1.0702"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under Concentration-time (AUC)</title>
        <time_frame>pre-dose and at 0.25, 0.5, 0.75, 1.0, 1.5, 2.0, 3.0, 4.0, 6.0, 8.0, 10, 12, and 24 hours</time_frame>
        <population>PK Substudy Population</population>
        <group_list>
          <group group_id="O1">
            <title>JKB 121, 5 mg</title>
            <description>JKB 121, 5 mg twice daily
JKB-121: 5 mg twice daily</description>
          </group>
          <group group_id="O2">
            <title>JKB 121, 10 mg</title>
            <description>JKB 121, 10 mg twice daily
JKB-121: 10 mg twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under Concentration-time (AUC)</title>
          <population>PK Substudy Population</population>
          <units>h*ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>time 0 to infinity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.50" spread="13.578"/>
                    <measurement group_id="O2" value="71.24" spread="16.562"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>time 0 to time of last quantifiable concentration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.29" spread="9.443"/>
                    <measurement group_id="O2" value="46.55" spread="5.312"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>time 0 to 12 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.29" spread="9.443"/>
                    <measurement group_id="O2" value="50.44" spread="5.388"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Half-life</title>
        <time_frame>pre-dose and at 0.25, 0.5, 0.75, 1.0, 1.5, 2.0, 3.0, 4.0, 6.0, 8.0, 10, 12, and 24 hours</time_frame>
        <population>PK Substudy Population</population>
        <group_list>
          <group group_id="O1">
            <title>JKB 121, 5 mg</title>
            <description>JKB 121, 5 mg twice daily
JKB-121: 5 mg twice daily</description>
          </group>
          <group group_id="O2">
            <title>JKB 121, 10 mg</title>
            <description>JKB 121, 10 mg twice daily
JKB-121: 10 mg twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Half-life</title>
          <population>PK Substudy Population</population>
          <units>h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.55" spread="1.439"/>
                    <measurement group_id="O2" value="6.95" spread="2.670"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 month</time_frame>
      <group_list>
        <group group_id="E1">
          <title>JKB 5 mg Twice Daily</title>
          <description>JKB 121, 5 mg twice daily</description>
        </group>
        <group group_id="E2">
          <title>Placebo Twice Daily</title>
          <description>Placebo, twice daily</description>
        </group>
        <group group_id="E3">
          <title>JKB 121 10 mg Twice Daily</title>
          <description>JKB 121, 10 mg twice daily</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <description>Deemed by PI and Sponsor not be attributable to study drug</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute on Chronic Hypoxemic Respiratory Failure</sub_title>
                <description>Deemed not attributable to study drub</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="21"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="22"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="21"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Abnormal dreams</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Nasopharynitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oralpharyngeal pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Nasal Congetion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>This is a pilot study to assess safety and tolerability of JKB 121 in patients with biopsy-proven NASH. There The study was underpowered to detect rare events.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Manal F. Abdelmalek</name_or_title>
      <organization>Duke University</organization>
      <phone>919-684-8356</phone>
      <email>manal.abdelmalek@duke.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

